Workflow tools offer significant productivity and efficiency

NASHUA, NH and VIENNA, AUSTRIA – March 2, 2016 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today an industry first tomosynthesis Computer-Aided Detection (CAD) solution and workflow tool. The technology will be introduced in Europe and will be available for demonstration in the iCAD booth (Expo X1, Booth # 554- lower level) during the European Congress of Radiology (ECR) meeting, from March 2-6, 2016 in Vienna, Austria. This is the latest innovative solution available with iCAD’s PowerLook Advanced Mammography Platform (AMP).

“The launch of this powerful solution demonstrates our commitment to remain on the forefront of cancer detection and workflow efficiency,” said Ken Ferry, CEO of iCAD. “Cancer detection solutions have proven to be effective for 2D mammography in assisting radiologists to identify cancer in earlier stages, when it may be more effectively treated. We believe our concurrent read software for breast tomosynthesis will change how radiologists read tomosynthesis studies creating an improved reading experience and a more efficient workflow while also aiding in the detection of cancer.”

A typical 2D mammogram involves examining two images per breast, while tomosynthesis can produce hundreds of images, significantly increasing the interpretation time for radiologists. iCAD’s breast tomosynthesis cancer detection solution analyzes each image identifying potential areas of interest in the tomosynthesis data set and blends those areas of interest onto a synthetic 2D image so that they are visible on a single image of the breast. The enhanced synthetic 2D image is also linked to the 3D tomosynthesis dataset, creating an efficient and effective navigation tool for radiologists and decreasing reading time.

An iCAD clinical study demonstrated a significant reduction in radiologist reading time with iCAD’s tomosynthesis concurrent CAD. This ground-breaking technology is pending CE mark which we anticipate in March 2016; FDA clearance is anticipated later in 2016.

“Using the tomosynthesis CAD solution from iCAD, Inc. is an excellent, innovative and reliable entry gate to the diagnosis. It summarizes the read saving precious reading time and reaches the end point quickly.” Said Dr. Laurent Lévy, Institut de Radiologie de Paris.

In addition, iCAD will showcase its iReveal automated breast density solution. iReveal provides a standardized assessment of breast tissue to assist radiologists in determining the patient’s appropriate breast density category.

“As 40% of mammography age women will have dense breasts at some point in their lives, knowing the degree of breast density can be crucial information for patients and doctors alike. iReveal can help radiologists avoid unnecessary follow up for their patients while identifying women who may benefit from additional screening,” Mr. Ferry added.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or or

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at


For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030


For iCAD media inquiries:

Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881